Cardiff Oncology Files 8-K for Reg FD, Financials

Ticker: CRDF · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1213037

Cardiff Oncology, Inc. 8-K Filing Summary
FieldDetail
CompanyCardiff Oncology, Inc. (CRDF)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, 8-K, compliance, financial-disclosure

TL;DR

**CRDF filed an 8-K for regulatory disclosure and financials, standard compliance.**

AI Summary

Cardiff Oncology, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to provide financial statements and exhibits. This filing indicates that the company, trading under the symbol CRDF on the Nasdaq Capital Market, is fulfilling its reporting obligations. For investors, this matters because it signals the company's adherence to regulatory transparency, which is crucial for maintaining investor confidence and providing timely information about its operations and financial health.

Why It Matters

This filing ensures Cardiff Oncology, Inc. remains compliant with SEC regulations, providing transparency to investors regarding any material non-public information and its financial status.

Risk Assessment

Risk Level: low — This 8-K filing is a routine regulatory disclosure and does not inherently present new risks or significant changes to the company's operations.

Analyst Insight

A smart investor would note this routine filing as a sign of ongoing regulatory compliance, but would look for the specific content of the Regulation FD disclosure and financial exhibits for any material information that could impact investment decisions.

Key Players & Entities

  • Cardiff Oncology, Inc. (company) — the registrant filing the 8-K
  • Nasdaq Capital Market (company) — the exchange where Cardiff Oncology's Common Stock is registered
  • CRDF (company) — the trading symbol for Cardiff Oncology's Common Stock
  • January 8, 2024 (date) — the date of the earliest event reported and the filing date

FAQ

What is the primary purpose of Cardiff Oncology, Inc.'s 8-K filing dated January 8, 2024?

The primary purpose of Cardiff Oncology, Inc.'s 8-K filing dated January 8, 2024, is to disclose information under Regulation FD and to provide financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

On which stock exchange is Cardiff Oncology, Inc.'s Common Stock registered?

Cardiff Oncology, Inc.'s Common Stock is registered on the Nasdaq Capital Market, as stated under 'Name of each exchange on which registered: Nasdaq Capital Market'.

What is the trading symbol for Cardiff Oncology, Inc.'s Common Stock?

The trading symbol for Cardiff Oncology, Inc.'s Common Stock is CRDF, as listed under 'Trading Symbol(s) CRDF'.

What is the business address of Cardiff Oncology, Inc.?

The business address of Cardiff Oncology, Inc. is 11055 Flintkote Avenue, San Diego, CA 92121, according to the 'BUSINESS ADDRESS' section of the filing.

What was Cardiff Oncology, Inc.'s former company name before March 4, 2013?

Before March 4, 2013, Cardiff Oncology, Inc. was formerly known as Trovagene, Inc., as indicated by 'FORMER COMPANY: FORMER CONFORMED NAME: Trovagene, Inc. DATE OF NAME CHANGE: 20130304'.

Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-01-08 09:12:29

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Cardiff Oncology , Inc. (the "Company") intends to conduct meetings with third parties in which its corporate slide presentation will be presented. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and the document attached as Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits. 99.1 Cardiff Oncology, Inc. Corporate Presentation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 CARDIFF ONCOLOGY, INC. By: /s/ Mark Erlander Mark Erlander Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.